Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation
Reid W. Merryman(Harvard University), Philippe Armand(Harvard University), Robert Redd(Harvard University), Jennifer R. Brown(Dana-Farber Cancer Institute), Oreofe O. Odejide(Dana-Farber Cancer Institute), Margaret A. Shipp(Broad Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Hyesun Park(Brigham and Women's Hospital), Gulrayz Ahmed(Medical College of Wisconsin), Kristin M McHugh(Dana-Farber Cancer Institute), Alex F. Herrera(City of Hope), Yi‐Bin Chen(Massachusetts General Hospital), Caron A. Jacobson(Dana-Farber Cancer Institute), Arnold S. Freedman(Otsuka (Japan)), Parastoo B. Dahi(Memorial Sloan Kettering Cancer Center), Erin M. Parry(Broad Institute), Erin Jeter(Dana-Farber Cancer Institute), Heather A. Jacene(Brigham and Women's Hospital), Matthew S. Davids(Dana-Farber Cancer Institute), Eric D. Jacobsen(Dana-Farber Cancer Institute), Ann S. LaCasce(Otsuka (Japan)), Jennifer L. Crombie(Dana-Farber Cancer Institute), David C. Fisher(Dana-Farber Cancer Institute), Austin I. Kim(Dana-Farber Cancer Institute), Samuel Y. Ng(National Cancer Institute), Eleanor Taranto(Unknown)
Cited by 19
Related Papers
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
|New England Journal of Medicine|2014|3.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k